RESUMEN
A recently developed semiquantitative thin-layer chromatographic (SQ-TLC) assay has been employed in postmarketing surveillance of antimalarial medicines used in Malawi prior to HPLC assay. Both methods gave analogous results in a significant majority of the samples, with a good correlation (r = 0.9012) for the active pharmaceutical ingredients of the dosage forms assayed. Artemether-containing medicines had the highest percentage (92.67%) of samples with comparable results for both assays. The lowest percentage (66.67%) was observed in artesunate-containing medicines. The SQ-TLC method was validated for specificity, accuracy, precision, linearity, and stability according to the International Conference on Harmonisation guidelines, with the results falling within acceptable limits. For specificity, retention factor values of the test samples and reference standards were comparable, while accuracy and precision of 91.1 ± 5.7% were obtained for all samples. The method was linear in the range 1.0-2.0 µg/spot with a correlation coefficient of r = 0.9783. Stability tests also fell within acceptable limits. In this study, we present the validation of the SQ-TLC method and propose its adoption as a rapid screening tool for field estimation of the quality of antimalarial and other essential medicines in Malawi and other parts of the developing world prior to a more accurate HPLC assay.
RESUMEN
This study, conducted as part of our overall goal of regular pharmacovigilance of antimalarial medicines, reports on the quality of 132 artemisinin-based antimalarial medicines distributed in Ghana and Togo. Three methods were employed in the quality evaluation-basic (colorimetric) tests for establishing the identity of the requisite active pharmaceutical ingredients (APIs), semi-quantitative TLC assay for the identification and estimation of API content, and HPLC assay for a more accurate quantification of API content. From the basic tests, only one sample totally lacked API. The HPLC assay, however, showed that 83.7% of the ACTs and 57.9% of the artemisinin-based monotherapies failed to comply with international pharmacopoeia requirements due to insufficient API content. In most of the ACTs, the artemisinin component was usually the insufficient API. Generally, there was a good correlation between the HPLC and SQ-TLC assays. The overall failure rates for both locally manufactured (77.3%) and imported medicines (77.5%) were comparable. Similarly the unregistered medicines recorded a slightly higher overall failure rate (84.7%) than registered medicines (70.8%). Only two instances of possible cross-border exchange of medicines were observed and there was little difference between the medicine quality of collections from border towns and those from inland parts of both countries.
RESUMEN
In the asymmetric unit of the title compound, 2C(7)H(9)ClN(+)·C(9)H(6)O(4) (2-)·2H(2)O, there are two crystallographically independent cations, one dianion and two water mol-ecules. The dihedral angle between the two carboxyl-ate groups of the dianion is 78.1â (2)°. In the crystal, the components are held together by N-Hâ¯O, O-Hâ¯O and C-Hâ¯O hydrogen bonds, forming a layer parallel to the bc plane, with the hydro-philic and hydro-phobic groups located in the inner and outer regions of the layers, respectively.
RESUMEN
The title compound, C(20)H(16)O(5), {systematic name: 5-hydr-oxy-7-(4-hydroxy-phen-yl)-2,2-dimethyl-2H,6H-benzo[1,2-b:5,4-b']dipyran-6-one}, was obtained by demethyl-ation of the biologically active related compound, 4-O-methyl-alpinum-iso-flavone. The mol-ecular structure of the title compound is characterized by a fused tricyclic system that contains an approximately planar benzopyrone ring fragment. The six membered pyran ring adopts a half-chair conformation. Both ring systems show an out-of-plane twist. The dihedral angle between the mean plane of the benzopyrone system and the benzene ring is 54.29â (3)°. The mol-ecules are linked by O-Hâ¯O hydrogen bonds, forming a mol-ecular tape running along the b axis.